Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Condition:   HER2-positive Breast Cancer Intervention:   Drug: [18F]-FDG Sponsor:   University of Alabama at Birmingham Not yet recruiting

Source: ClinicalTrials.gov - February 18, 2020 Category: Research Source Type: clinical trials